Novartis Starts Strategic Review Of Sandoz Generic Drug Unit: Ceo

Novartis starts strategic review of Sandoz generic drug unit: CEO

CNBC Television

Expect concrete decision before the end of the year on Sandoz, says Novartis CEO

CNBC International News

Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company

CNBC International News

Novartis Raises Outlook After Sandoz Generics Spinoff

Bloomberg Television

'Regulators are seeing the importance' of generic drugs, Sandoz CEO says

CNBC International News

Sandoz will be a long-term stable business if it can get its cost structure right, Novasecta says

CNBC International News

Novartis-CEO: Strategische Überprüfung von Sandoz war lange geplant

awp Finanznachrichten AG

Novartis CEO: Setting Up Sandoz for Next Wave of Growth

Bloomberg Television

Biosimilars benefit patients, doctors and healthcare systems

How were things back THEN, when the first biosimilar was developed and launched?

Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off

CNBC International News

Novartis-CEO: Sandoz wird zu solidem Wachstum zurückkehren

awp Finanznachrichten AG

Novartis CEO on new cancer therapy programs

CNBC Television

Novartis Financial Results Q3 2021

Novartis ESG Investor Day 2021: 6 key takeaways

Novartis CEO: We're moving toward filing Covid drug from Molecular Partners with FDA

CNBC Television

Innovative medicines business returning to growth, Novartis CEO says

CNBC International News

How are core Therapeutic Areas central to Novartis strategy?

Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

CNBC Television

Biologics revolutionized healthcare